Reuters logo
BRIEF-Bristol Myers Squibb-says U.S. patent on hepatitis b drug baraclude invalidated by Delaware federal court
February 12, 2013 / 2:45 PM / in 5 years

BRIEF-Bristol Myers Squibb-says U.S. patent on hepatitis b drug baraclude invalidated by Delaware federal court

Feb 12 (Reuters) - Bristol-Myers Squibb Co : * Says U.S. patent on hepatitis b drug baraclude invalidated by Delaware

federal court * Says loses patent challenge from generic drugmaker Teva * Says believes court decision is “incorrect,” considering appeal of decision * Says U.S. baraclude patent lapses February 2015, declines comment on whether

Teva might be allowed to launch generic before then

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below